0.7059
price down icon8.61%   -0.0665
 
loading
前日終値:
$0.7724
開ける:
$0.704
24時間の取引高:
9.37M
Relative Volume:
3.03
時価総額:
$71.13M
収益:
$147.75M
当期純損益:
$-284.23M
株価収益率:
-0.2409
EPS:
-2.93
ネットキャッシュフロー:
$-317.54M
1週間 パフォーマンス:
+27.30%
1か月 パフォーマンス:
+33.16%
6か月 パフォーマンス:
+75.99%
1年 パフォーマンス:
-58.84%
1日の値動き範囲:
Value
$0.6512
$0.7872
1週間の範囲:
Value
$0.54
$0.8775
52週間の値動き範囲:
Value
$0.18
$2.80

Fibrogen Inc Stock (FGEN) Company Profile

Name
名前
Fibrogen Inc
Name
セクター
Healthcare (1169)
Name
電話
415-978-1200
Name
住所
350 BAY STREET, SAN FRANCISCO, CA
Name
職員
486
Name
Twitter
@FibroGenInc
Name
次回の収益日
2024-11-04
Name
最新のSEC提出書
Name
FGEN's Discussions on Twitter

FGEN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
FGEN
Fibrogen Inc
0.7059 71.13M 147.75M -284.23M -317.54M -2.93
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.24 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
700.33 76.56B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
644.48 39.16B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
250.59 32.44B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
120.01 28.77B 3.30B -501.07M 1.03B -2.1146

Fibrogen Inc Stock (FGEN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-08-08 ダウングレード BofA Securities Neutral → Underperform
2023-06-26 ダウングレード BofA Securities Buy → Neutral
2023-06-26 ダウングレード Raymond James Outperform → Mkt Perform
2023-06-26 ダウングレード Stifel Buy → Hold
2023-06-26 ダウングレード William Blair Outperform → Mkt Perform
2023-06-02 アップグレード Stifel Hold → Buy
2023-01-31 アップグレード William Blair Mkt Perform → Outperform
2023-01-26 アップグレード Raymond James Mkt Perform → Outperform
2023-01-05 アップグレード BofA Securities Neutral → Buy
2021-09-22 ダウングレード Goldman Neutral → Sell
2021-08-20 アップグレード Raymond James Underperform → Mkt Perform
2021-07-16 ダウングレード BofA Securities Buy → Neutral
2021-07-16 ダウングレード Stifel Buy → Hold
2021-04-07 ダウングレード H.C. Wainwright Buy → Neutral
2021-04-07 ダウングレード Mizuho Buy → Neutral
2021-03-31 アップグレード BofA Securities Neutral → Buy
2021-03-02 ダウングレード Jefferies Buy → Hold
2021-02-01 開始されました H.C. Wainwright Buy
2020-10-26 開始されました Raymond James Underperform
2020-07-10 再開されました Stifel Buy
2020-05-01 開始されました Cowen Market Perform
2020-04-27 開始されました BofA/Merrill Neutral
2019-05-29 再開されました Goldman Neutral
2019-05-10 ダウングレード William Blair Outperform → Mkt Perform
2019-04-12 開始されました Piper Jaffray Neutral
2019-02-11 再開されました Stifel Buy
2018-12-19 アップグレード Citigroup Neutral → Buy
2017-08-08 繰り返されました Leerink Partners Outperform
2017-08-08 繰り返されました Stifel Buy
2017-07-21 ダウングレード Goldman Buy → Neutral
2017-07-11 開始されました Jefferies Buy
2016-02-11 アップグレード Credit Suisse Neutral → Outperform
2016-01-21 開始されました Credit Suisse Neutral
2015-12-04 開始されました Citigroup Buy
2015-09-23 開始されました Lake Street Hold
2015-07-29 開始されました Citigroup Buy
2015-07-20 アップグレード Goldman Neutral → Buy
2014-12-09 開始されました Stifel Buy
すべてを表示

Fibrogen Inc (FGEN) 最新ニュース

pulisher
06:49 AM

FibroGen sells China biz to AstraZeneca for $160 M - BSA bureau

06:49 AM
pulisher
Feb 21, 2025

FibroGen sells China unit to AstraZeneca for $160 million - MSN

Feb 21, 2025
pulisher
Feb 21, 2025

AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal - Dealbreaker

Feb 21, 2025
pulisher
Feb 21, 2025

Moody's Lifts AstraZeneca's Ratings, Revises Outlook to Stable -February 21, 2025 at 11:51 am EST - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

FibroGen stock holds $10 target amid China unit sale - Investing.com

Feb 21, 2025
pulisher
Feb 21, 2025

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 46% Share Price Rise - Simply Wall St

Feb 21, 2025
pulisher
Feb 21, 2025

FibroGen stock holds $10 target amid China unit sale By Investing.com - Investing.com UK

Feb 21, 2025
pulisher
Feb 21, 2025

StockNews.com Initiates Coverage on FibroGen (NASDAQ:FGEN) - MarketBeat

Feb 21, 2025
pulisher
Feb 20, 2025

This Small Cap Soared Following Subsidiary Sale Announcement Worth $160M - The Globe and Mail

Feb 20, 2025
pulisher
Feb 20, 2025

FibroGen to sell China business, extend cash runway to focus on cancer drugs - The Business Journals

Feb 20, 2025
pulisher
Feb 20, 2025

FibroGen sells China unit to AstraZeneca for $160m - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

FibroGen (FGEN) to Release Earnings on Monday - MarketBeat

Feb 20, 2025
pulisher
Feb 20, 2025

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million - Benzinga

Feb 20, 2025
pulisher
Feb 20, 2025

FibroGen sells China business to AstraZeneca - The Pharma Letter

Feb 20, 2025
pulisher
Feb 20, 2025

AstraZeneca deepens China presence with FibroGen deal - BioPharma Dive

Feb 20, 2025
pulisher
Feb 20, 2025

AstraZeneca to buy FibroGen's China unit for $160 million - MSN

Feb 20, 2025
pulisher
Feb 20, 2025

FibroGen stock soars on China unit sale - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

FibroGen Sells Subsidiary to AstraZeneca for $160M - TipRanks

Feb 20, 2025
pulisher
Feb 20, 2025

FibroGen soars on $160 mln China unit sale to AstraZeneca - TradingView

Feb 20, 2025
pulisher
Feb 20, 2025

AstraZeneca to buy FibroGen's China unit for $160 million -February 20, 2025 at 07:04 am EST - Marketscreener.com

Feb 20, 2025
pulisher
Feb 20, 2025

FibroGen Sells China Unit to AstraZeneca in $160 Million DealNews and Statistics - IndexBox, Inc.

Feb 20, 2025
pulisher
Feb 20, 2025

FibroGen sells China unit to AstraZeneca in deal worth $160 million By Reuters - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

FibroGen sells China unit to AstraZeneca in deal worth $160 million -February 20, 2025 at 06:40 am EST - Marketscreener.com

Feb 20, 2025
pulisher
Feb 20, 2025

FibroGen sells China unit to AstraZeneca for $160 million (FGEN:NASDAQ) - Seeking Alpha

Feb 20, 2025
pulisher
Feb 20, 2025

FibroGen Announces Sale of China Subsidiary to AstraZeneca for Approximately $160 Million - Nasdaq

Feb 20, 2025
pulisher
Feb 20, 2025

FibroGen sells China unit to AstraZeneca in deal worth $160 million - Yahoo Finance UK

Feb 20, 2025
pulisher
Feb 20, 2025

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million - GlobeNewswire

Feb 20, 2025
pulisher
Feb 19, 2025

Drug developers struggle in 2024; Fibrogen, Acadia, Atai post gains - BioWorld Online

Feb 19, 2025
pulisher
Feb 18, 2025

FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 5.2% in January - Defense World

Feb 18, 2025
pulisher
Feb 06, 2025

FibroGen Inc: Weathering Stock Market Storms with 51.09M Market Cap - The InvestChronicle

Feb 06, 2025
pulisher
Feb 05, 2025

Trading Day Triumph: FibroGen Inc (FGEN) Ends at 0.46, a -2.61 Surge/Plunge - The Dwinnex

Feb 05, 2025
pulisher
Feb 05, 2025

FibroGen (NASDAQ:FGEN) Earns Hold Rating from Analysts at StockNews.com - Defense World

Feb 05, 2025
pulisher
Jan 28, 2025

JPMorgan Chase & Co. Has $668,000 Position in FibroGen, Inc. (NASDAQ:FGEN) - Defense World

Jan 28, 2025
pulisher
Jan 26, 2025

Assenagon Asset Management S.A. Sells 415,812 Shares of FibroGen, Inc. (NASDAQ:FGEN) - Defense World

Jan 26, 2025
pulisher
Jan 21, 2025

FibroGen (NASDAQ:FGEN) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat

Jan 21, 2025
pulisher
Jan 15, 2025

FibroGen Inc (NASDAQ: FGEN) Is Down -5.77% – Can It Revive? - Stocks Register

Jan 15, 2025
pulisher
Jan 13, 2025

FibroGen, Inc. (NASDAQ:FGEN) Shares Purchased by Geode Capital Management LLC - Defense World

Jan 13, 2025
pulisher
Jan 06, 2025

Perspective Therapeutics Appoints FibroGen Veteran Juan Graham as New CFO to Drive Growth Strategy - StockTitan

Jan 06, 2025
pulisher
Jan 05, 2025

State Street Corp Lowers Holdings in FibroGen, Inc. (NASDAQ:FGEN) - Defense World

Jan 05, 2025
pulisher
Jan 02, 2025

Cue Biopharma (NASDAQ:CUE) versus FibroGen (NASDAQ:FGEN) Head-To-Head Comparison - Defense World

Jan 02, 2025
pulisher
Jan 01, 2025

FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com - Defense World

Jan 01, 2025
pulisher
Jan 01, 2025

FibroGen (NASDAQ:FGEN) Coverage Initiated at StockNews.com - MarketBeat

Jan 01, 2025
pulisher
Dec 31, 2024

Court of Chancery Applies Well-Settled Principles To Dismiss Malone/Caremark ‘Hybrid’ Claims - JD Supra

Dec 31, 2024
pulisher
Dec 25, 2024

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise - Simply Wall St

Dec 25, 2024
pulisher
Dec 24, 2024

FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com - Defense World

Dec 24, 2024
pulisher
Dec 24, 2024

Recent Investment Analysts’ Ratings Updates for FibroGen (FGEN) - Defense World

Dec 24, 2024
pulisher
Dec 23, 2024

Fmr LLC Boosts Holdings in FibroGen, Inc. (NASDAQ:FGEN) - Defense World

Dec 23, 2024
pulisher
Dec 20, 2024

HC Wainwright Comments on FibroGen FY2024 Earnings - Defense World

Dec 20, 2024
pulisher
Dec 19, 2024

HC Wainwright Upgrades FibroGen (NASDAQ:FGEN) to Strong-Buy - Defense World

Dec 19, 2024
pulisher
Dec 19, 2024

HC Wainwright Estimates FibroGen FY2026 Earnings - Defense World

Dec 19, 2024
pulisher
Dec 18, 2024

FibroGen started at buy by H.C. Wainwright (FGEN:NASDAQ) - Seeking Alpha

Dec 18, 2024

Fibrogen Inc (FGEN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Fibrogen Inc (FGEN) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Wettig Thane
CEO
Mar 07 '24
Buy
1.91
50,000
95,470
470,178
$33.42
price up icon 0.27%
$81.06
price down icon 3.05%
$361.10
price down icon 1.70%
$22.12
price down icon 4.08%
biotechnology ONC
$255.37
price up icon 4.57%
$120.01
price up icon 1.81%
大文字化:     |  ボリューム (24 時間):